FDA
-
-
-
-
-
-
-
Tarsus Pharmaceuticals to acquire Alkeus for up to $800M
-
-
-
-
-
-
-
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
-
-
-
-
-
-
-
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
-
-
-
-
-
-
-
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
-
-
-
-
-
-
-
Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
-
-
-
-
-
-
-
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
-
-
-
-
-
-
-
Tarsus to Participate in Upcoming Investor Conference
-
334,272 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


